Inactive Instrument

Press Releases Lightlake Therapeutics OTC Bulletin Board

Equities

US53224T1051

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

2023	Indivior completes acquisition of Opiant Pharmaceuticals	AN
2023	Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OPIANT PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	02/23/02	AQ
OPIANT PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	02/23/02	AQ
OPIANT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	28/23/28	AQ
OPIANT PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	08/23/08	AQ
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC	08/23/08	GL
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC	06/23/06	GL
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC	06/23/06	AQ
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose	20/23/20	GL
OPIANT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	10/23/10	AQ
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT	07/23/07	BU
SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations	01/22/01	PR
Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose	23/22/23	AQ
OPIANT PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	16/22/16	AQ
US pharma giants Indivior and Opiant to merge in $145m deal	15/22/15	AQ
EQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNT	15/22/15	PR
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT	15/22/15	BU
SHAREHOLDER ALERT: Weiss Law Investigates Opiant Pharmaceuticals, Inc.	15/22/15	PR
OPIANT PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	15/22/15	AQ
OPIANT PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	15/22/15	AQ
OPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant Pharmaceuticals	14/22/14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lightlake Therapeutics OTC Bulletin Board

Equities

US53224T1051

Press Releases

Filters